As described previously, human NEU-1, the ERC catalytic subunit, is known, after activation of its sialidase activity by EDP, to be involved in several pathophysiological contexts as cancers [7,8,9,10,11,13,14,44], diabetes [3], atherosclerosis [4], and nonalcoholic steatohepatitis [6]. This evidence concerns the gene NEU1 and cancer.